Overview

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Citalopram
Quetiapine Fumarate
Criteria
Inclusion Criteria:

- Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.

- Be able to understand and comply with the requirements of the study.

- Able to understand and provide written informed consent

Exclusion Criteria:

- Patients (female) must not be pregnant or lactating

- Current or past diagnosis of stroke or transient ischemic attack (TIA).